Welcome to MetrioPharm!


MetrioPharm AG is a clinical stage pharmaceutical biotech company developing new medications against chronic immune disorders. Our focus is on Immune-Mediated Inflammatory Diseases (IMIDs) such as psoriasis, arthritis and multiple sclerosis.

An estimated 50 million people are affected alone in the Western industrialized countries, worldwide there are more than 300 million patients. Almost all IMIDs become chronic. Symptoms include: Pain, discomfort, organ damage, loss of quality of life, increased co-morbidity, and shortened life expectancy.

Our drug candidates have shown the potential to be significantly safer and more tolerable than existing therapies. MetrioPharm's lead compound MP1032 is currently in phase II clinical testing.

MetrioPharm AG was founded in 2007.
The company is headquartered in Zurich and operates a research facility in Berlin.